Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Update

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totaling 21,539 shares, a growth of 610.2% from the August 15th total of 3,033 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 885,605 shares, the short-interest ratio is currently 0.0 days.

Emmaus Life Sciences Stock Up 11.4%

Shares of Emmaus Life Sciences stock opened at $0.06 on Friday. Emmaus Life Sciences has a 52 week low of $0.01 and a 52 week high of $0.09. The business has a 50 day moving average price of $0.03 and a 200-day moving average price of $0.02. The company has a market cap of $4.04 million, a PE ratio of -0.64 and a beta of 10.07.

Emmaus Life Sciences (OTCMKTS:EMMA) last announced its earnings results on Friday, August 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $6.32 million for the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.